Respira Therapeutics and United Therapeutics Corp have begun a strategic collaboration for the development and exclusive license of Respira’s inhaled drug-device product, RT234, for pulmonary hypertension.
United Therapeutics will provide Respira with non-dilutive development funding to advance RT234 through FDA approval. In addition, United Therapeutics will be the lead investor in Respira’s Series B preferred stock financing.
